This trial is active, not recruiting.

Condition leukemia
Treatments clofarabine, cytarabine
Phase phase 2
Sponsor Comprehensive Cancer Center of Wake Forest University
Collaborator National Cancer Institute (NCI)
Start date February 2005
End date November 2008
Trial size 39 participants
Trial identifier NCT01656031, 21204 Phase 2, CCCWFU-21204, CCCWFU-BG04-519, ILEX-CCCWFU-21204


RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying clofarabine when given together with cytarabine to see how well they work in treating patients with refractory or relapsed acute myeloid leukemia or acute lymphoblastic leukemia.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking open label
Primary purpose treatment
high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days

Primary Outcomes

Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML
time frame: 5 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Pathologic confirmation of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) - No M3 AML - Meets 1 of the following criteria: - In first relapse - In second relapse after a second complete remission (CR) that lasted ≥ 3 months - Refractory to initial induction therapy - No symptomatic CNS involvement PATIENT CHARACTERISTICS: - ECOG performance status ≤ 2 - Creatinine < 2 mg/dL - Bilirubin ≤ 2 mg/dL - AST and ALT ≤ 4 times upper limit of normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 2 weeks after completing study treatment - Ejection fraction ≥ 45% by echocardiogram - No active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant - No psychiatric disorders that would interfere with giving consent, study participation, or follow-up procedures - No other severe concurrent disease that would preclude study treatment PRIOR CONCURRENT THERAPY: - At least 1 week since prior therapy and recovered - No other concurrent chemotherapy - Hydroxyurea to control WBC count before starting study treatment allowed - No concurrent corticosteroids unless used for diseases other than leukemia - No concurrent palliative radiotherapy - No concurrent growth factors (e.g., epoetin alfa, filgrastim [G-CSF], or sargramostim [GM-CSF]) in patients with AML

Additional Information

Official title A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Description OBJECTIVES: - Determine the response rate in adult patients with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia treated with high-dose cytarabine followed by clofarabine. OUTLINE: This is an open-label phase II study. Patients are stratified according to diagnosis (acute myeloid leukemia vs acute lymphoblastic leukemia Phase II: Patients receive high-dose cytarabine followed by clofarabine (at the dose determined in phase I) on days 1-3. After completion of study treatment, patients are followed periodically for up to 5 years. PROJECTED ACCRUAL: A total of 39 patients were accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Comprehensive Cancer Center of Wake Forest University.